Dr. Mohini Rajasagi, Daiichi Sankyo, is a precision medicine and translational oncology leader with deep expertise spanning immuno-oncology and antibody–drug conjugates. She earned her PhD in Immunology from the German Cancer Research Center (DKFZ), Heidelberg, and completed postdoctoral training at Dana‑Farber Cancer Institute, where she led the systematic identification and validation of tumor‑specific neoantigens for cancer immunotherapy. This work helped found a biotech company later acquired by BioNTech, supporting multiple ongoing phase 3 neoantigen vaccine trials. Dr. Rajasagi has since built a strong industry track record advancing transformative oncology therapies at Daiichi Sankyo, Merck, Pfizer, and Bristol Myers Squibb. She has contributed to the regulatory success of multiple programs, including ADCs such as Enhertu, Datroway, and enfortumab vedotin, as well as immuno‑oncology programs including Keytruda, across breast, genitourinary, gastrointestinal, gynecologic cancers, and non‑small cell lung cancer.